Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder

Clinical Pharmacokinetics

Volumn 49, Issue 5, 2010, Pages 335-342

  Siegmund, Werner ^a   Sillén, Ulla ^b   Läckgren, Göran ^c   Schnabel, Frieder ^d   Mürtz, Gerd ^d   Feustel, Cornelia ^d  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d APOGEPHA Arzneimittel GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDE; BENZILIC ACID DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; PROPIVERINE; PROPIVERINE N OXIDE; PROPIVERINE N-OXIDE;

AGE; ARTICLE; BLOOD; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; OVERACTIVE BLADDER; PRESCHOOL CHILD;

AGE FACTORS; BENZILATES; CHILD; CHILD, PRESCHOOL; CYCLIC N-OXIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; URINARY BLADDER, OVERACTIVE;

EID: 79951999155     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11319990-000000000-00000     Document Type: Article

References (31)

1. Festge OA, Tischer W, Rosenbaum KD, et al. Urodynamic function tests after P4 use in children [in German]. Padiatr Grenzgeb 1982; 21: 43-52
2. Heller K. Treatment of children with an unstable bladder using the new anti-cholinergic drug Mictonorm [in German]. Padiatr Padol 1982; 17: 115-20
3. Festge OA, Tischer W, Christiansen C, et al. Urodynamically controlled effect of propiverin on the function of the lower urinary tract in children with enuresis [in German]. Kinderarztl Prax 1986; 54: 677-84
4. Nentwich HJ. Therapy of enuresis with a pediatric tablet of propiverine (Mictonettes) [in German]. Kinderarztl Prax 1986; 54: 329-33
5. Alloussi S, Goepel M, Richter AE, et al. Therapy for overactive detrusor using propiverine [in German]. Urologe A 2005; 44: 382-6
6. Grigoleit U, Murtz G, Laschke S, et al. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity: a retrospective study. Eur Urol 2006; 49: 1114-20
7. Otto-Unger G. Treatment of the unstable bladder in children with the anticholinergic agent propiverin hydrochloride (Mictonorm/Mictonets) [in German]. Z Urol Nephrol 1985; 78: 145-52
8. Schulte-Baukloh H, Murtz G, Henne T, et al. Urodynamic effects of propi-verine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis. BJU Int 2006; 97: 355-8
9. Marschall-Kehrel D, Feustel C, Persson de Geeter C, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Eur Urol 2009; 55: 729-36
10. European Medicines Agency. Note for guidance on good clinical practice (CPMP/ICH/135/95). London: European Medicines Agency, 2002 Jul [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf [Accessed 2010 Mar 18]
11. Nevéus T, von Gontard A, Hoebeke P, et al. The standardization of termi-nology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol 2006; 176: 314-24
12. Meisel P, Langner S, Siegmund W. In-vitro binding of propiverine hydrochloride and some of its metabolites to serum albumin in man. J Pharm Pharmacol 1997; 49: 270-2
13. Wuest M, Weiss A, Waelbroeck M, et al. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol 2006; 374: 87-97
14. Wuest M, Hecht J, Christ T, et al. Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol 2005; 145: 608-19
15. Matsushima S, Inada H, Asai T, et al. Propiverine hydrochloride, an antipollakiuric agent, inhibits the activity of actomyosin ATPase from the urinary bladder. Eur J Pharmacol 1997; 333: 93-7
16. May K, Westphal K, Giessmann T, et al. Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms. J Clin Pharmacol 2008; 48: 570-9
17. Giessmann T, May K, Moritz KU, et al. Disposition of propiverine and its metabolites is influenced by MRP2 [abstract]. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: R156
18. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-67
19. Edginton AN, Schmitt W, Voith B, et al. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 2006; 45: 683-704
20. Bartelink IH, Rademaker CM, Schobben AF, et al. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45: 1077-97
21. Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32
22. Alloussi S, Schonberger B, Murtz G, et al. Treatment of the urge syndrome with propiverine in therapeutic practice: efficacy and safety in 4390 patients [in German]. Urologe B 2000; 40: 367-73
23. May K, Giessmann T, Wegner D, et al. Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination. Eur J Clin Pharmacol 2008 Nov; 64 (11): 1085-92
24. Oertel R, Kilian B, Siegmund W, et al. Determination of propiverine and its metabolites in rat samples by liquid chromatography-tandem mass spectrometry. J Chromatogr A 2007; 1149: 121-6
25. Haustein KO, Huller G. On the pharmacokinetics and metabolism of propiverine in man. Eur J Drug Metab Pharmacokinet 1988; 13: 81-90
26. Metabolism studies with propiverine. Data on file, Apogepha, 2004
27. Donovan SF, Pescatore MC. Method for measuring the logarithm of the octanol-water partition coefficient by using short octadecyl-poly(vinyl alcohol) high-performanceliquid chromatography columns. J Chromatogr A 2002; 952:47-61
28. Zimmermann C, Gutmann H, Hruz P, et al. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5mRNA expression along the human intestinal tract. Drug Metab Dispos 2005; 33: 219-24
29. Englund G, Rorsman F, Ronnblom A, et al. Regional levels of drug trans-porters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2cells. Eur J Pharm Sci 2006;29: 269-77
30. Zhang QY, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999; 27: 804-9
31. Paine MF, Khalighi M, Fisher JM, et al. Characterizationofinterintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-62